A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Estinyl Side Effects, and Drug Interactions - Ethinyl Estradiol
Estinyl Side Effects, and Drug Interactions - Ethinyl Estradiol
SIDE EFFECTS
(See WARNINGS regarding
induction of neoplasia, adverse effects on the fetus, increased
incidence of gallbladder
disease, the adverse effects similar to those of oral
contraceptives, including thromboembolism.) The following additional
adverse reactions have been reported with estrogenic
therapy, including oral
contraceptives:
Genitourinary system: Breakthrough bleeding, spotting, change
in menstrual flow: dysmenorrhea; premenstrual-like syndrome; amenorrhea
during and after treatment, increase in size of uterine
fibromyomata; vaginal candidiasis; change in cervical
eversion and in degree
of cervical secretion;
cystitis-like syndrome.
Breasts: Tenderness, enlargement, secretion.
Gastrointestinal: Nausea, vomiting; abdominal
cramps, bloating; cholestatic jaundice.
Skin: Chloasma or melasma
which may persist when drug
is discontinued; erythema multiforme; erythema
nodosum; hemorrhagic
eruption; loss of scalp
hair; hirsutism.
Eyes: Steepening of corneal curvature; intolerance
to contact lenses.
CNS: Headache, migraine, dizziness; mental
depression; chorea.
Miscellaneous: Increase or decrease in weight; reduced carbohydrate
tolerance; aggravation of porphyria; edema; changes in libido.
DRUG INTERACTIONS
Certain endocrine
and liver function
tests may be affected by estrogen-containing oral contraceptives.
The following similar changes may be expected with larger doses
of estrogen:
Increased sulfobromophthalein
retention; increased prothrombin
and factors VII, VIII, IX, and X; decreased antithrombin
3; increased norepinephrine-induced platel et aggregation; increased
thyroid binding globulin
(TBG) leading to increased circulating total thyroid
hormone, as measured by PBI, T4 by column, or T4
by radioimmunoassay. Free T3 resin uptake is decreased,
reflecting the elevated TBG; free T4 concentration is
unaltered: impaired glucose
tolerance; decreased pregnanediol
excretion; reduced response
to metyrapone test;
reduced serum folate concentration;
increased serum triglyceride
and phospholipid
concentration.
top
